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Edited by Veli-Pekka LehtoAbstract Osteoblastic diﬀerentiation is an essential part of
bone formation. Dimethyl sulfoxide (DMSO) is a water miscible
solvent that is used extensively for receptor ligands in osteoblast
studies. However, little is known about its eﬀects on osteoblasto-
genic precursor cells. In this study, we have used a murine preos-
teoblast cell line MC3T3-E1 cells to demonstrate that DMSO
eﬀectively induces osteoblastic diﬀerentiation of MC3T3-E1
cells via the activation of Runx2 and osterix and is dependent
upon the protein kinase C (PKC) pathways. We further demon-
strated that prolonged activation of PKC pathways is suﬃcient
to induce osteoblastic diﬀerentiation, possibly via the activation
of PKD/PKCl.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Osteoblasts1. Introduction
In normal bone remodeling or bone turnover, osteoblastic
bone formation and osteoblastic bone resorption is coupled
in a precise and orchestrated manner. Osteoblastic diﬀerentia-
tion is an essential part of bone formation. Several groups of
proteins are necessary for osteoblastic diﬀerentiation, such as
bone morphogenetic proteins (BMPs) and transcription
factors such as Runx2 and osterix (Osx) [1,2].
Dimethyl sulfoxide (DMSO; (CH3)2SO) is a water miscible
solvent that serves as powerful solvents that dissolve most
water-insoluble drugs [3]. DMSO possesses anti-inﬂammatory
properties [4], as well as the ability to act as a free radical scav-
enger [5]. Thus, its properties have been exploited in the treat-
ment of dermatological, rheumatic, and renal manifestations
of amyloidosis. Depending on the cellular context and proba-Abbreviations: DMSO, dimethyl sulfoxide; PKC, protein kinase C;
BMP, bone morphogenetic protein; Osx, osterix; GFx, GF 109203X;
PMA, phorbol 12-myristate 13-acetate; Tris, Trizma base; TX, Triton-
X100; ALP, alkaline phosphatase; PNPP, p-nitrophenyl phosphate;
MAPKs, MAP kinases
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of inducing or inhibiting cell proliferation, apoptosis and/or
diﬀerentiation [6]. DMSO induces the diﬀerentiation of many
cell types including leukemia cells and mammary adenocarci-
noma LA7 cells [7,8]. DMSO induces diﬀerentiation of LA7
cells into mammary cells with milk production, which origi-
nally requires the supplementation of lactogenic hormones.
Therefore, it is recently developed as an in vitro model system
for studying mammary cells diﬀerentiation [8]. In osteoblast
studies, DMSO is used extensively as a solvent for receptor li-
gands such as rosiglitazone for peroxisome proliferator-acti-
vated receptor gamma [9]. However, limited data is available
on the eﬀect of DMSO on the osteoblastic diﬀerentiation.
In this study, we investigated the eﬀect of DMSO on the pro-
liferation and diﬀerentiation of MC3T3-E1 cells, a non-trans-
formed murine cell line derived from neonatal mouse
calvariae. Treatment with BMPs, such as BMP2, induces
MC3T3-E1 cells to undergo osteoblastic diﬀerentiation, which
leads to the formation of bone nodules in vitro [10]. We dem-
onstrated that DMSO eﬀectively induces osteoblastic diﬀeren-
tiation of MC3T3-E1 cells via the activation of Runx2 and Osx
and is dependent upon the protein kinase C (PKC) pathway.2. Materials and methods
2.1. Chemicals
All chemicals were purchased from Sigma–Aldrich Co. (St. Louis,
MA, USA) unless otherwise stated.
2.2. Cell culture
MC3T3-E1 cells (clone 4; obtained from American Type Culture
Collection, Rockville, MD, USA) were maintained in complete modi-
ﬁed Eagles medium (MEM) alpha medium (aMEM; Invitrogen, San
Diego, CA, USA) supplemented with 10% fetal bovine serum (JRH
Biosciences, Lenexa, KS, USA) in a humidiﬁed 5% CO2 atmosphere
at 37 C. Cells were passaged before reaching conﬂuence.2.3. Cell diﬀerentiation
During cell diﬀerentiation studies, MC3T3-E1 cells were plated at
5 · 104 cells per cm2, cultivated to complete conﬂuence and then trea-
ted with increasing concentrations of DMSO (0.02–1%). For bone
nodules formation, MC3T3-E1 cells were cultured in osteogenic med-
ium containing 400 lM ascorbic acid and 5 mM b-glycerophosphate to
provide inorganic phosphate. PKC activator, phorbol 12-myristate
13-acetate (PMA) and inhibitor, GF 109203X (GFx), both obtained
from Calbiochem-Novabiochem (San Diego, CA, USA) were em-
ployed to modulate the activity of PKC in MC3T3-E1 cells. Cells were
normally pre-incubated with PMA (1 lM) or GFx (2 lM) for 1 h and
then diﬀerentiated with DMSO for 6 days in phosphorylation and 15
days in bone nodules formation studies. As DMSO was used as solvent
for PMA and GFx, equal volume of DMSO that contributed to lessblished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀect of DMSO on the proliferation of MC3T3-E1 cells.
MC3T3-E1 cells were cultured for 2 days in normal (circle) or
osteogenic medium (box) with increasing concentrations of DMSO.
Cell proliferation was assessed by MTT reduction. All readings were
calculated by comparing with the untreated control cells, which was set
as 100%. *P < 0.01 compared with no-DMSO treatment group,
unpaired Students t test. Results are the means ± S.E.M. of 2
independent experiments (n = 5).
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containing PKC modulators and DMSO were replenished every 2
days. Cell diﬀerentiation experiments were repeated for three times
and data from representative experiments are shown.
2.4. Cell proliferation assays
Cell proliferation studies were performed as previously described
using MTT (GE Healthcare, Piscataway, NJ, USA) assays [11]. After
treatment with DMSO (0.02–1%) for 2 days, MTT was added at a ﬁnal
concentration of 0.5 mg/ml for 3 h, cells were solubilized with isopro-
panol containing 0.1% sodium dodecyl sulfate and 0.04 N hydrochloric
acid, and the absorbance measured at 570 nm. All experiments were re-
peated for three times.
2.5. Total protein extraction, Western blot analysis and antibodies
MC3T3-E1 cells were washed with PBS and then lysed with lysis
buﬀer containing 50 mM Trizma base (Tris)–Cl at pH 8, 150 mM so-
dium chloride, 1% Triton-X100 (TX), 1· aprotinin, 1 mM PMSF,
1 mM sodium orthovanadate, and 1· Complete protease inhibitor
cocktail (Roche Molecular Biochemicals, Mannheim, Germany) at
4 C for 15 min. Western blot analysis was performed as previously de-
scribed [12] using polyclonal antibodies against phosphorylated p44/
p42 MAP kinase (MAPK) (p-Erk1/2), phosphorylated pan-PKC,
phosphorylated PKCh (p-PKCh), phosphorylated PKD/PKCl
(p-PKD/PKCl), as well as monoclonal antibodies against Erk2 and
diﬀerent isotypes of PKC that were obtained from Cell Signaling Tech-
nology (Beverly, MA, USA) and Transduction Laboratories (Lexing-
ton, KY, USA), respectively. Data presented are representative of
independent experiments repeated twice with proteins extracted from
duplicate treatment.
2.6. Total RNA extraction and gene expression analysis by real time
quantitative PCR
Transcript expression of Runx2, Osx, and alkaline phosphatase
(ALP) was determined using reverse transcription (RT) followed by
real-time TaqMan quantitative PCR (qPCR) analysis performed in a
ABI 7700 sequence detector (Applied Biosystems Inc., Foster City,
CA, USA). Total RNA was isolated using TRI Reagent (Molecular
Research Center Inc., Cincinnati, OH, USA). First-strand cDNA
was synthesized using random hexamers and M-MLV reverse trans-
criptase (Promega Co., Madison, MI, USA). TAMRA labeled probes
and PCR reagents were obtained from ABI. PCRs were performed in
triplicate and data obtained were analyzed using the comparative CT
method (ABI) with signals normalized to 18S signal for each sample.
All experiments were repeated for 3 times.
2.7. Assessment of osteoblastic cell diﬀerentiation
Cells were incubated without or with DMSO (0.02–1%) in normal or
osteogenic culture media for selective time periods. ALP activity was
measured as p-nitrophenol produced from the hydrolysis of p-nitro-
phenyl phosphate (PNPP) [13]. In brief, cells were washed with ice-cold
PBS, lysed with 50 mM Tris, pH 7.4, and 0.1% TX, and incubated with
2-amino-2-methyl-1-propanol buﬀer (0.5 M, pH 10.4) containing
10 mM PNPP at 37 C for 15–30 min. The reaction was stopped by
the addition of NaOH (ﬁnal concentration, 0.5 M) and the absorbance
measured at 410 nm. Enzyme activity was normalized to the protein
content determined using Protein Assay Kit (Bio-Rad). Experiments
were performed in triplicate wells and data shown are representative
of two independent experiments.
2.8. Histochemical staining
Cells were washed twice with ice-cold PBS and then ﬁxed in ice-
cold ﬁxative (10% formalin in PBS) for 15 min. After washed with
deionized water, ﬁxed cells were stained with Fast Blue RR Salt
and Napthol AS-BI Phosphate for 30 min, and the reaction stopped
by washing the cells with surplus deionized water. Mineralized matrix
was detected using Von Kossa staining by treating ﬁxed cells with 5%
silver nitrate for 30 min, followed by subsequent washes with 5% so-
dium carbonate in 10% formalin for 1 min and 5% sodium thiosulfate
for 5 min. The reaction was stopped by washing the cells thrice with
deionized water. Alternatively, ﬁxed cells were stained with 1% aliza-
rin S solution, pH 4.2 for 15 min and then were washed thoroughly
with deionized water.2.9. Statistical analysis
Statistical analyses were performed using Two-way ANOVA. Bon-
ferroni analyses were used for post hoc examination of the ANOVA
results (P < 0.0001). All statistical analyses were performed using the
Statview for Macintosh software package (SAS Institute Inc., NC,
USA, version 5).3. Result
3.1. Eﬀect of DMSO on cellular proliferation of MC3T3-E1
cells
No signiﬁcant diﬀerence was observed in cell proliferation in
cells incubated with DMSO at 0.5% (v/v) or below (Fig. 1).
However, 1% DMSO signiﬁcantly reduced the proliferation
of MC3T3-E1 to 93.3 ± 2.0% (Fig. 1; n = 5, *P < 0.001).
While osteogenic medium alone increased proliferation to
133.7 ± 4.2%, 1% DMSO signiﬁcantly suppressed the enhance-
ment to 123.7 ± 3.6% when compared to control. Viable cell
count conﬁrmed that osteogenic medium increased the cell
number of MC3T3-E1 cells and DMSO signiﬁcantly reduced
the cell number in both normal and osteogenic media (data
not shown).
3.2. DMSO-induced formation of bone nodules via increasing
number of ALP expressing cells
At high concentrations of DMSO (0.5% and 1%), there were
noticeable morphological changes and formation of mineral-
ized bone-like nodules (Fig. 2A). The mineralization pheno-
type was also assessed and conﬁrmed by alizarin red S
staining (Fig. 2B). To determine whether DMSO-induced
osteoblastic diﬀerentiation or only accelerated the rate of min-
eralization, samples were assayed for ALP activity. MC3T3-E1
cells cultured with DMSO resulted in a signiﬁcant and dose-
dependent increase in ALP activity (Fig. 3A). Maximal ALP
activity was observed with 0.5% DMSO, which reached a pla-
teau with 1% DMSO (Fig. 3A). ALP staining conﬁrmed
DMSO increased ALP-positive cells upon and was comparable
to that of control treatment with 50 ng/ml BMP2 (Fig. 3B).
Fig. 2. DMSO-induced bone nodules formation in MC3T3-E1 cells.
(A) Von Kossa staining was performed to visualize mineralization of
MC3T3-E1 cells cultured for 15 days in normal (Control) or osteogenic
medium (Osteog.) with increasing concentrations of DMSO as
indicated. (B) Alizarin Red staining of mineralized nodules in
MC3T3-E1 cells treated with 1% (v/v) DMSO. Bar represents 62.5 lm.
Fig. 4. DMSO induced the transcript expression of Runx2 and Osx in
MC3T3-E1 cells. MC3T3-E1 cells were cultured for 5 days in normal
medium and either left untreated (CTL), or treated with BMP2 (50 ng/
ml; BMP2-50) or 1% DMSO. Results from qPCR analysis of Runx2
(lower panel) and Osx (upper panel) are presented as means ± S.E.M.
of 2 independent experiments (each in triplicate). *P < 0.0005 and
**P < 0.05, unpaired t test, compared with control (n = 6).
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transcription factors, Runx2 and Osx
Treatment of MC3T3-E1 cells with 1% DMSO increased
Runx2 expression signiﬁcantly by 1.89-fold and Osx expres-
sion by 1.39-fold, respectively, (Fig. 4; n = 6, *P < 0.0005).
Thus, DMSO-induced osteoblastic diﬀerentiation and bone
formation through modulation of these 2 bone speciﬁc tran-
scription factors that are determinants of bone formation.
Low concentration of BMP2 (50 ng/ml) increased ALP expres-
sion and upregulated Osx transcription but not mRNA of
Runx2.
3.4. Involvement of Raf/MEK/extracellular signal-regulated
kinase (Erk) in the DMSO-induced osteoblastic
diﬀerentiation
Erk (also known as p44/p42 MAPK) plays diﬀerential roles
in proliferation and diﬀerentiation and its phosphorylation
regulates the transcription of Runx2 [14,15]. Thus, DMSOFig. 3. DMSO-induced ALP expression in MC3T3-E1 cells. MC3T3-E1 ce
medium (box) with increasing concentrations of DMSO as indicated. (A) A
represent the means ± S.E.M. of a representative independent experiment
Students t test, n = 4). (B) ALP staining revealed expression of ALP in MC3T
or BMP2 (50 ng/ml). Bar represents 62.5 lm.might mediate its biological actions via the activation of Erk.
When MC3T3-E1 cells were just conﬂuent, Erk1 and Erk2
were activated and their expression diminished after culturing
for 6 days in normal medium (p-Erk1/2; Fig. 5A). However, in
the presence of 1% DMSO, higher level of p-Erk1/2 expression
was observed, suggesting that DMSO-induced osteoblastic
diﬀerentiation is associated with the sustained activation of
Erk in MC3T3-E1 cells.lls were cultured for 8 days in normal medium (circle) or osteogenic
LP activity was determined and normalized to protein content. Data
out of 3 (*P < 0.05 compared with no-DMSO control by unpaired
3-E1 cells cultured for 8 days either untreated, treated with 1% DMSO
Fig. 5. DMSO activates the phosphorylation of Erks and PKCs in MC3T3-E1 cells. MC3T3-E1 cells were cultured for 6 days in normal medium and
either left untreated or with 1% DMSO. Total proteins collected on day 0 is denoted as ‘‘-’’. Activation of (A) Erk1/2; (B) PKCa and -d; (C) PKCh
was detected by phospho-speciﬁc and respective non-phosphorylation state-speciﬁc antibodies as indicated; (D) PKD/PKCl activation was examined
in MC3T3-E1 cells cultured for 5 days in normal medium () or with 1% DMSO (+) and with either control solvent (Sol), GFx (2 lM) or PMA
(1 lM) as indicated. Expression of b-actin was used as internal control as indicated.
Fig. 6. Eﬀect of PKC modulation on osteoblastic diﬀerentiation of
MC3T3-E1 cells. MC3T3-E1 cells were cultured for 15 days in
osteogenic medium with 1% DMSO 5 or 15 days. GFx (2 lM; GFx-2)
or PMA (1 lM; PMA-1) were supplemented as indicated. (A) Alizarin
Red staining of bone nodules and (B) ALP activity was determined.
Mean ALP activity obtained using control solvent (0.05% DMSO) was
designated as 1. *P < 0.01 compared to control, by Bonferroni post hoc
test when ANOVA (P < 0.0001); **P < 0.01 compared to DMSO
treatment; #P < 0.01 compared to PMA alone.
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diﬀerentiation of MC3T3-E1 cells
PKC comprises a family of serine–threonine kinases that
play pivotal roles in the regulation of cell proliferation and dif-
ferentiation [16]. Using DMSO-induced osteoblastic diﬀerenti-
ation as model system, we evaluated the role of PKC pathways
in mediating osteoblastic diﬀerentiation. Both PKCa and -d
were activated in conﬂuent MC3T3-E1 cells, but their expres-
sion was not altered by DMSO treatment (Fig. 5B). In con-
trast, PKCh was activated by DMSO but not by cell
conﬂuence (p-PKCh; Fig. 5C). There was also a slight increase
in p-PKCh when MC3T3-E1 cells were cultured in normal
medium for 6 days. The activation paralleled the expression
of ALP and bone nodules formation. Total PKCa, -d, and -h
expression was not aﬀected. Prolonged DMSO treatment also
upregulated the expression of p-PKD (also known as phospho-
PKCl) (Fig. 5D). However, unlike PKCh, the expression of to-
tal PKD/PKCl was also upregulated (Fig. 5D, middle panel).
PKD is activated via PKC-dependent pathways [17]. Thus,
we further investigated the involvement of PKD in DMSO-in-
duced osteoblastic diﬀerentiation by modulating the PKC
activities. As expected, the expression of p-PKD and total
PKD was markedly attenuated by PKC inhibitor GFx but
augmented by PKC activator PMA (Fig. 5D). Next, we exam-
ined the prolonged eﬀect of PKD inhibition on the bone nod-
ules formation. DMSO-induced formation of bone nodules
was completely blocked by either exposing MC3T3-E1 cells
to GFx for 5 days or throughout the diﬀerentiation period
(15 days) (Fig. 6A). In contrast, PMA enhanced the bone
forming eﬀect of DMSO (Fig. 6A). PMA alone could also in-
duce bone nodules formation though less eﬀective than com-
bining with DMSO. It is noteworthy that formation of bone
nodules could partially be reversed upon GFx washout at
day 5 when there was a continuous supplementation of
DMSO. This supports the hypothesis that DMSO-induced
osteoblastic diﬀerentiation via the activation of PKD. Our
ﬁndings were conﬁrmed by measuring the ALP activity.
DMSO alone increased ALP activity by 1.5-fold (Fig. 6B).
GFx suppressed the induced ALP activity to basal expression
level, whereas PMA augmented ALP activity to 2.9-fold that
of the control cells. PMA alone upregulated the ALP activity
by 1.8-fold. Taken together, our results suggest the involve-
ment of PKD in mediating the DMSO-induced osteoblastic
diﬀerentiation.4. Discussion
This report shows that DMSO signiﬁcantly inhibited cell
proliferation of MC3T3-E1 cells at a concentration of 1% (v/
v) and DMSO-induced osteoblastic diﬀerentiation of
MC3T3-E1 cells. The osteoblastogenic eﬀect of DMSO was
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vation of PKD via the PKC pathways.
The preosteoblast MC3T3-E1 cell line is an excellent cell dif-
ferentiation model that simulates the events of early osteoblas-
togenesis. Diﬀerentiation of MC3T3-E1 cells to osteoblasts by
exposure to BMP2 was shown to be associated with induction
of the bone-speciﬁc transcription factors such as Runx2 and
Osx [18,19]. Runx2 and Osx are hypothesized to act on diﬀer-
ent stages of osteoblastic diﬀerentiation, i.e., commitment and
terminal diﬀerentiation, respectively [19]. In this work, treat-
ment with DMSO resulted in a signiﬁcant induction of both
Runx2 and Osx in MC3T3-E1 cells, suggesting that DMSO
is capable of inducing the diﬀerentiation of preosteoblast cells
into mature osteoblasts. We hypothesize the use of DMSO-in-
duced osteoblastic diﬀerentiation of MC3T3-E1 cells as an
in vitro model system for the study of mechanisms controlling
osteoblastic diﬀerentiation.
Activity of Erks regulates the transcription of Runx2 during
the extracellular matrices induced osteoblastic diﬀerentiation
of MC3T3-E1 cells [20]. In line with previous ﬁndings, we de-
tected a noticeable increase in the expression of activated Erks.
The functional roles of Erk in cellular diﬀerentiation have been
paradoxical. Dependent upon the cellular context, the Erk
pathway suppresses cellular diﬀerentiation such as adipogene-
sis [21] while induces diﬀerentiation of pheochromocytoma
PC12 cells [22]. Likewise, in osteoblastic diﬀerentiation, activa-
tion of MAPKs enhances the expression of ALP [23].
Using DMSO-induced osteoblastic diﬀerentiation of preoste-
oblast cells as model system, we have also examined the role of
PKD in osteoblastic diﬀerentiation. Functional roles of PKC
pathways in regulating the transcriptional activity and post-
translational modiﬁcation of Runx2 have previously been dem-
onstrated [24]. However, little is known on the phenotypic
changes associated with prolonged PKC activation. This report
provides the ﬁrst evidence that prolonged activation of PKC
pathways alone is suﬃcient to induce osteoblastic diﬀerentia-
tion, possibly via the activation of PKD/PKCl. PKD/PKCl
is a serine protein kinase that responds to PMA treatment
[25]. Unlike other PKC isotypes, PKD lacks C2 domain that
plays essential roles in the Ca2+ sensitivity [26]. Activation of
PKD in turn requires the upstream PKCh signaling. Treatment
of MC3T3-E1 cells with GFx, which is capable of inhibiting
PKC but not PKD activities [9], abolished the DMSO-mediated
expression and activation of PKD (Fig. 5D; lanes 3 and 4). Con-
comitantly, GFx inhibitedDMSO-inducedALP expression and
bone nodules formation inMC3T3-E1 cells. As it has previously
been suggested that PKCh is the upstream kinase of PKD/
PKCl [27], GFx might inhibit PKCh, thereby indirectly inhib-
ited the phosphorylation of PKD. Consistent with previous
ﬁndings that inhibition of PKD markedly reduced the BMP2-
induced expression of ALP and osteocalcin [28], GFx inhibits
DMSO-induced bone nodules formation. Our studies further
demonstrate that the activation of PKD enhances both ALP
expression and bone nodules formation via PKC activation.
In conclusion, we have demonstrated that DMSO is a pow-
erful inducer of osteoblastic diﬀerentiation in MC3T3-E1 cells.
Our results also show that DMSO-induced osteoblastic diﬀer-
entiation of MC3T3-E1 cells represents a model system to
study the functional roles of biochemical pathways in inducing
or regulating osteoblastic diﬀerentiation and provides clues to
alternative therapeutic approaches by providing additional
pathways to bone formation.Acknowledgements: We are thankful to Lilian Jin, Patrick Chu and
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